The frequency of late-stage MSI cancers is lower than MSS cancers which reflects the lower metastatic risk of MSI cancers [105], however the prognostic benefit conferred by MSI was lost in the metastatic setting where BRAF mutant/MSI cancers had similarly poor survival rates as BRAF mutant/MSS cancers [106, 107]. This evidence concerns the gene BRAF and cancer.